Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136,380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY; Protocol 039 Study Group. Hirsch MS, et al. Among authors: chen j. Clin Infect Dis. 2003 Oct 15;37(8):1119-24. doi: 10.1086/378063. Epub 2003 Sep 18. Clin Infect Dis. 2003. PMID: 14523778 Clinical Trial.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Steigbigel RT, et al. Among authors: chen j. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975. N Engl J Med. 2008. PMID: 18650512 Free article. Clinical Trial.
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Cooper DA, et al. Among authors: chen j. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978. N Engl J Med. 2008. PMID: 18650513 Free article. Clinical Trial.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team. Grinsztejn B, et al. Among authors: chen j. Lancet. 2007 Apr 14;369(9569):1261-1269. doi: 10.1016/S0140-6736(07)60597-2. Lancet. 2007. PMID: 17434401 Clinical Trial.
Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. Wenning LA, et al. Among authors: chen j. Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8. doi: 10.1128/AAC.00005-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625763 Free PMC article. Clinical Trial.
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ. Nguyen BY, et al. Among authors: chen j. Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Ann N Y Acad Sci. 2011. PMID: 21434946 Review.
136,380 results
You have reached the last available page of results. Please see the User Guide for more information.